Adrenal Cancer
Welcome,         Profile    Billing    Logout  
 3 Companies   1 Product   10 Mechanisms of Action   1 Trial   17 News 
  • ||||||||||  Biomarker; Trial termination:  Evaluation of Molecular Markers in Adrenal Tumors (clinicaltrials.gov) -  Jan 13, 2018   
    P=N/A,  N=74, Terminated, 
    Completed -> Terminated; Slow/insufficient accrual
  • ||||||||||  Biomarker; Enrollment change; Trial completion:  Evaluation of Molecular Markers in Adrenal Tumors (clinicaltrials.gov) -  Dec 6, 2017   
    P=N/A,  N=74, Completed, 
    Recruiting -> Completed | N=500 -> 71
  • ||||||||||  Enrollment change; Trial primary completion date:  Possible New Therapy for Advanced Cancer (clinicaltrials.gov) -  Nov 18, 2014   
    P1/2,  N=9, Terminated, 
    N=36 -> 9 | Trial primary completion date: Dec 2015 -> Mar 2014
  • ||||||||||  Trial termination:  Possible New Therapy for Advanced Cancer (clinicaltrials.gov) -  Nov 14, 2014   
    P1/2,  N=9, Terminated, 
    Recruiting -> Terminated; Business decision by the sponsor during Phase 1.
  • ||||||||||  lidocaine/heparin (URG101) / Urigen
    Journal:  The 'omics' of adrenocortical tumours for personalized medicine. (Pubmed Central) -  Feb 4, 2014   
    This Review describes the progress that has been made towards classification of adrenocortical tumours to date based on key genomic approaches. In addition, the potential for the development and use of various molecular tools to personalize the management of patients with adrenocortical tumours is discussed.